Hiroshi Kawamoto
Taisho Pharmaceutical Co.
8 Papers
46 Citations
Hiroshi Kawamoto is an academic researcher from Taisho Pharmaceutical Co.. The author has contributed to research in topics: Mood disorders & Panic disorder. The author has an hindex of 3, co-authored 8 publications.
Chat about Author
Papers
Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist.
Ryo Suzuki,Dai Nozawa,Futamura Aya,Rie Nishikawa-Shimono,Masahito Abe,Nobutaka Hattori,Hiroshi Ohta,Yuko Araki,Daiji Kambe,Mari Ohmichi,Seiken Tokura,Takeshi Aoki,Norikazu Ohtake,Hiroshi Kawamoto +13 more
TL;DR: Accumulating evidence regarding ADME profiles indicates that the predicted human half-life of 27e should be 1.2-1.4h, suggesting that 27e might be useful for treating primary insomnia while exhibiting a low risk of next-day residual somnolence.
22
Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia
Futamura Aya,Ryo Suzuki,Yunoshin Tamura,Hiroshi Kawamoto,Mari Ohmichi,Noriko Hino,Yuichi Tokumaru,Sora Kirinuki,Tetsuaki Hiyoshi,Takeshi Aoki,Daiji Kambe,Dai Nozawa +11 more
TL;DR: Compound (-)-3h (ORN0829; investigation code name, TS-142) was selected as a viable candidate and is currently in clinical development for the treatment of insomnia, indicating a predicted human half-life of 0.9-2.0 h.
16
Identification of highly selective and potent orexin receptor 1 antagonists derived from a dual orexin receptor 1/2 antagonist based on the structural framework of pyrazoylethylbenzamide.
Futamura Aya,Dai Nozawa,Yuko Araki,Yunoshin Tamura,Seiken Tokura,Hiroshi Kawamoto,Yuichi Tokumaru,Sora Kakihara,Takeshi Aoki,Norikazu Ohtake +9 more
TL;DR: The design, synthesis, and structure activity relationships of the novel class of pyrazolylethylbenzamide orexin receptor 1-selective antagonists are described and the identification of N-ethyl-5-fluoro-N-{(2S)-1-[5-(4-fluorophenyl)-2H-tetrazol-2-yl]propan- 2-yl}.
13
Patent
Heteroaryl-pyrazole derivative
Toshio Nakamura,Kazunari Sakagami,Konishi Kazuhide,Kanako Yamamoto,Masuda Seiji,Yohei Matsuda,Kumiko Okada,Tsuyoshi Shibata,Hiroshi Ohta,Akito Yasuhara,Hiroshi Kawamoto,Hideaki Amada,Hiroki Urabe,Rie Nishikawa,Shuhei Kashiwa +14 more
- 11 Aug 2011
TL;DR: In this article, a compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a phamaceutic accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive compulsive disorder, social anxiety disorder), posttraumatic stress disorder, acute stress disorder), schizophrenia, Alzheimer's disease
9
Patent
Ethinyl-pyrazole derivative
Toshio Nakamura,Kazunari Sakagami,Konishi Kazuhide,Kanako Yamamoto,Masuda Seiji,Yohei Matsuda,Kumiko Okada,Tsuyoshi Shibata,Hiroshi Ohta,Akito Yasuhara,Hiroshi Kawamoto +10 more
- 29 Jul 2011
TL;DR: In this paper, a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors is provided.
3